Document is current
Any future updates will be listed below
-
Authors
Taylor, Chelsea A. https://orcid.org/0000-0002-1635-4167
Watson, Robert A.
Tong, Orion https://orcid.org/0000-0002-0659-5944
Ye, Weiyu https://orcid.org/0000-0002-8983-0355
Nassiri, Isar
Gilchrist, James J. https://orcid.org/0000-0003-2045-6788
de los Aires, Alba Verge
Sharma, Piyush Kumar https://orcid.org/0000-0002-6247-3503
Koturan, Surya
Cooper, Rosalin A.
Woodcock, Victoria K. https://orcid.org/0000-0001-7656-728X
Jungkurth, Elsita
Shine, Brian
Coupe, Nicholas
Payne, Miranda J.
Church, David N. https://orcid.org/0000-0002-4617-962X
Naranbhai, Vivek
Groha, Stefan
Emery, Paul https://orcid.org/0000-0002-7429-8482
Mankia, Kulveer
Freedman, Matthew L.
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Middleton, Mark R. https://orcid.org/0000-0003-0167-1685
Gusev, Alexander https://orcid.org/0000-0002-7980-4620
Fairfax, Benjamin P. https://orcid.org/0000-0001-7413-5002
-
Funding
Funding for this research was provided by:
Wellcome Trust (201488/Z/16/Z, BST00070)
DH | National Institute for Health Research
NIHR Oxford Biomedical Research Centre
RCUK | Engineering and Physical Sciences Research Council
The Clarendon Fund, St Edmund Hall, Oxford Oxford Australia Scholarship
Cancer Research UK (RCCTI\100019, S_3578)
Leeds Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 6 April 2022
Accepted: 18 October 2022
First Online: 16 December 2022
Competing interests
: C.A.T., R.A.W., O.T., W.Y., R.C., A.V.A., P.K.S., I.N., J.J.G. and A.G. declare no competing interests. M.R.M. reports grants from Roche, grants from AstraZeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees and other from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, personal fees from Kineta and personal fees from Silicon Therapeutics, all outside the submitted work. D.C. reports funding from Haliodx and consultancy for Merck. K.S. reports grants from Gilead, Eli Lilly and BMS and personal fees from UCB, AZD, Abbvie and Eli Lilly. P.E. performed consultancy for Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Galapagos, Gilead, Janssen, MSD, Eli Lilly, Novartis, Pfizer, Roche and Samsung and was involved in clinical trials for Abbvie, BMS, Eli Lilly, Novartis, Pfizer, Roche and Samsung. T.K.C. reports research/advisory boards/consultancy/honorarium (institutional and personal, paid and unpaid) from AstraZeneca, Aveo, Bayer, BMS, Eisai, EMD Serono, Exelixis, GSK, IQVA, Ipsen, Kanaph, Eli Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda and Tempest. Travel, accommodations, expenses, medical writing in relation to consulting, advisory roles or honoraria. Stock options: Pionyr and Tempest. Other: up-to-date royalties, CME-related events (for example, OncLIve, PVI and MJH Life Sciences) honoraria. NCI GU Steering Committee. Patents filed, royalties or other intellectual properties (no income as of current date): related to biomarkers of immune checkpoint blockers and ctDNA. No speaker’s bureau. B.P.F. received conference support from BMS and performed consultancy for UCB.
